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Background/Aims: Recently, several studies have revealed 
that diagnostic imaging can result in exposure to harmful 
levels of ionizing radiation in inflammatory bowel disease pa-
tients. However, the extent of radiation exposure in intestinal 
Behçet disease (BD) patients has not been documented. The 
aim of this study was to estimate the radiation exposure from 
abdominal imaging studies in intestinal BD patients. Meth-
ods: Patients with a diagnosis of intestinal BD established 
between January 1990 and March 2012 were investigated 
at a single tertiary academic medical center. The cumula-
tive effective dose (CED) was calculated retrospectively from 
standard tables and by counting the number of abdominal 
imaging studies performed. High exposure was defined as 
CED >50 mSv. Results: In total, 270 patients were included 
in the study. The mean CED was 41.3 mSv, and 28.1% of 
patients were exposed to high levels of radiation. Computed 
tomography (CT) accounted for 81.7% of the total effective 
dose. In multivariate analyses, predictors of high radiation 
exposure were azathioprine/6-mercaptopurine use, surgery, 
and hospitalization. Conclusions: Approximately a quarter 
of intestinal BD patients were exposed to harmful levels of 
diagnostic radiation, mainly from CT examination. Clinicians 
should reduce the number of unnecessary CT examinations 
and consider low-dose CT profiles or alternative modali-
ties such as magnetic resonance enterography. (Gut Liver 
2014;8:380-387)
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INTRODUCTION
The risks of protracted exposure to low-level ionizing radia-
tion, including diagnostic radiation, have been acknowledged 
for decades, although the carcinogenic potential resulting from 
diagnostic radiation exposure has been debatable.1 A study in-
volving 15 developed countries reported that between 0.6% and 
1.8% of all malignancies resulted from diagnostic medical ra-
diation.2 Irradiation with as little as 50 mili-Sieverts (mSv) from 
imaging-related radiation exposure has been implicated in the 
development of certain solid tumors, particularly of the large 
bowel and bladder.3
Inflammatory bowel disease (IBD) itself increases the risk 
of colorectal and small intestinal cancers4-6 and medications 
such as azathioprine, 6-mercaptopurine (6-MP), and infliximab 
are associated with an increased risk of lymphoma.7,8 This is 
of clinical concern for IBD patients, as IBD often presents at a 
young age and patients are thus repeatedly exposed to diag-
nostic medical radiation over the course of their disease, further 
increasing the risk of malignancy. Several recent studies ex-
amined radiation exposure from diagnostic medical imaging in 
IBD patients and reported that 5% to 24% of IBD patients have 
received potentially harmful levels of radiation, defined as ≥50 
mSv.9-14
Intestinal Behçet disease (BD) is diagnosed by the presence 
of typical intestinal ulcers and systemic symptoms meeting the 
BD diagnostic criteria.15 Similarly to IBD, including Crohn’s 
disease (CD) and ulcerative colitis, intestinal BD is a chronic 
IBD having a fluctuating course characterized by repeated epi-
sodes of relapse and remission.16 The chronic relapsing nature 
of intestinal BD often requires repeat diagnostic imaging. In 
addition, diagnostic imaging is essential for patients with in-
See editorial on page 333.
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testinal BD for perioperative evaluation because intestinal BD 
often requires surgical treatment due to the high frequency of 
complications, such as intestinal perforations and fistulas.17-19 
Radiation exposure from diagnostic imaging is expected to be 
become increasingly common for intestinal BD patients as it has 
for IBD patients, especially with increasing access to computed 
tomography (CT). However, the extent of diagnostic radiation 
exposure in patients with intestinal BD has never been specifi-
cally studied. Moreover, it would be valuable if patients at risk 
for a high level of radiation exposure could be identified, as this 
might help in minimizing the risk in these patients. Accord-
ingly, the objective of this study was to examine the cumulative 
effective ionizing radiation exposure from all abdominal imag-
ing studies in a large number of patients with intestinal BD. In 
addition, we sought to identify factors associated with exposure 
to high levels of diagnostic radiation.
MATERIALS AND METHODS
1. Study population and clinical evaluation
All patients with an established diagnosis of intestinal BD 
who were registered in the intestinal BD database at Severance 
Hospital, Yonsei University College of Medicine, Seoul, Korea, 
between January 1990 and March 2012, were eligible for in-
clusion in the study. Patients who were at least 18 years old at 
diagnosis and who had been followed up for at least 6 months 
were included. Baseline clinical, endoscopic, and laboratory 
characteristics were extracted from a prospectively-collected 
database. Information regarding hospitalization, operation, and 
medical treatment modalities during the follow-up periods was 
obtained by reviewing medical records.
Intestinal BD was diagnosed according to established criteria 
based on colonoscopic features and clinical manifestations.15 
Patients classified as definite, probable, and suspected were in-
cluded in the study.
Some patients were first diagnosed with intestinal BD during 
surgery performed due to an acute or complicated presentation 
such as perforation. All other patients underwent colonoscopy 
at the time of diagnosis to identify the location and shape of the 
intestinal ulcer. Lesions with less than five ulcers that were oval 
in shape, deep, had discrete borders, and were located in the 
ileocecal area were defined as typical ulcerations.20 Ulcerations 
that did not fulfill all of these criteria were defined as atypical. 
Surgery was defined as an intestinal resection related to intesti-
nal BD. The definition of hospitalization included only intestinal 
BD-related admissions.
Intestinal BD activity was measured using the disease activ-
ity index for intestinal Behçet disease (DAIBD), as described.21 
The DAIBD ranges in value from 0 to 325, with higher scores 
reflecting greater disease activity.
2. Determination of radiation exposure
Almost all imaging resulting in exposure to diagnostic medi-
cal radiation consisted of plain abdominal X-rays (AXR), CT 
scans of the abdomen and/or pelvis, CT enterography (CTE), 
small bowel follow-through (SBFT), and barium enema. The 
total effective dose of radiation received from AXR, SBFT, and 
barium enema was each calculated according to published 
standardized tables (Table 1).22 The effective dose for CT of the 
abdomen and/or pelvis and CTE were calculated by multiplying 
the dose-length product (DLP) by a factor of 0.015, which is the 
dose conversion factor for the abdomen and pelvis according to 
the guidelines provided in Publication 103 of the International 
Commission on Radiological Protection.23 When the DLP of CT 
of the abdomen and/or pelvis was not recorded in CT scan re-
ports it was estimated based upon published standardized tables 
(Table 1). Cumulative effective dose (CED) was calculated for 
each patient by summing the effective doses of radiation from 
the time of diagnosis of intestinal BD until the time of data 
review. High cumulative exposure to diagnostic radiation was 
defined as CED exceeding 50 mSv.
This study was approved by the Institutional Review Board of 
Severance Hospital, Seoul, Korea.
3. Statistical analysis
The software program SPSS version 12 (SPSS Inc., Chicago, 
IL, USA) was used for statistical analyses. The chi-square or 
Fisher exact test was used to compare categorical variables. 
Student t-test or the Mann-Whitney U test was used to com-
pare numerical variables between groups. p-values <0.05 were 
considered statistically significant. We constructed multivariate 
logistic regression models to identify independent factors asso-
ciated with high CED (≥50 mSv). Adjusted odds ratios (ORs) and 
95% confidence intervals (CIs) were calculated.
RESULTS
1. Patient demographics
A total of 270 patients with intestinal BD were included. 
Their mean age at diagnosis of BD, the onset of intestinal symp-
toms, and the diagnosis of intestinal BD were 38.7, 40.6, and 
41.4 years, respectively. Of 270 patients, 123 (45.6%) were men 
Table 1. Radiation Dose from Common Abdominal Imaging Studies
Imaging study Effective dose of radiation, mSv
Plain abdominal X-ray 0.7
CT abdomen 10
CT pelvis 10
Small bowel follow-through 3
Barium enema 7.2
CT, computed tomography.
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and the mean follow-up duration after diagnosis was 7.5 years 
(range, 0.5 to 22.3 years). The most common intestinal symptom 
and location were abdominal pain (217 patients, 80.4%) and 
ileocecal area (255 patients, 94.4%), respectively. Twenty-eight 
patients who were first diagnosed at the time of operation as 
having intestinal BD were excluded from the analysis of colo-
noscopy characteristics.
2. Diagnostic radiation exposure
The total number of abdominal imaging examinations among 
all patients was 3,114, of which 2,623 (84.2%), 433 (13.9%), 
50 (1.6%), and eight (0.3%) were AXR, CT (of these, 40 [1.3%] 
were CTE), SBFT, and barium enema, respectively. CT imaging 
accounted for 81.7% (9,103/11,146 mSv) of total effective dose 
from abdominal imaging studies (Fig. 1). The mean and median 
CED per patients from abdominal imaging were 41.3 and 15.8 
mSv, respectively. The annual mean and median effective dose 
were 11.1 and 1.4 mSv/yr, respectively. One hundred and sixty-
eight patients (62.2% of cohort) underwent at least one ab-
dominal imaging study. Seventy-six of the 270 patients (28.1%) 
received CED exceeding 50 mSv (Fig. 2).
3. Factors associated with high cumulative exposure to di-
agnostic radiation
Table 2 shows the differences between patients with a CED 
greater and less than 50 mSv. The mean age at diagnosis of 
intestinal BD, age at onset of intestinal symptoms, and age at 
diagnosis of BD were all significantly lower in patients with a 
CED ≥50 mSv than those with a CED <50 mSv. White blood cell 
count, erythrocyte sedimentation rate, C-reactive protein level, 
and DAIBD at diagnosis were significantly higher in patients 
with a CED ≥50 mSv than those with a CED <50 mSv, whereas 
albumin levels were significantly lower in patients with a CED 
≥50 mSv than those with a CED <50 mSv. Volcano-shaped 
ulcers were more common in patients with a CED ≥50 mSv, 
while oval and geographic-shaped ulcers were more common 
in patients with a CED <50 mSv. During the follow-up period, 
intestinal perforation and fistula occurred more frequently in 
patients with a CED ≥50 mSv than in those with a CED <50 
mSv. In addition, patients with a CED ≥50 mSv required more 
frequent corticosteroid therapy, azathiopurine (AZA)/6-MP 
therapy, surgical treatment, and hospitalization than those with 
a CED <50 mSv.
No statistical differences in terms of sex, disease duration, 
family history of BD, symptoms and signs of systemic BD, type 
of intestinal ulcer, or diagnostic subtype were observed between 
patients with a CED greater and less than 50 mSv. In a mul-
tivariate logistic regression analysis that included significant 
variables from the univariate analysis, AZA/6-MP use (OR, 2.60; 
95% CI, 1.10 to 6.16; p=0.030), surgery (OR, 3.35; 95% CI, 1.20 
to 9.39; p=0.022), and hospitalization (OR, 4.11; 95% CI, 1.32 to 
12.82; p=0.015) were independent explanatory factors associ-
ated with a high CED (Table 3).
DISCUSSION
Although several studies have reported significant diagnostic 
radiation exposure among patients with IBD, this study is the 
first to investigate the cumulative effective ionizing radiation 
exposure of patients with intestinal BD and to identify the sub-
groups of patients who are at greater risk of high cumulative 
exposure.
We found that a substantial proportion of intestinal BD pa-
tients were exposed to high doses of ionizing radiation from 
diagnostic tests. Over a mean follow-up period of 7.5 years, ap-
proximately a quarter of intestinal BD patients (28.1%) received 
cumulative doses in excess of 50 mSv, and the mean CED for 
intestinal BD was 41.3 mSv. Several recent studies investigat-
Fig. 1. Relative contribution of abdominal imaging studies to the cu-
mulative effective dose in patients with intestinal Behçet disease.
CT, computed tomography; SBFT, small bowel follow-through.
Fig. 2. Cumulative effective dose (CED) of abdominal imaging studies 
in patients with intestinal Behçet disease.
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Table 2. Univariate Analysis of Factors Associated with Cumulative Effective Dose ≥50 mSv
Factor CED <50 mSv (n=194) CED ≥50 mSv (n=76) p-value
Age at diagnosis of intestinal BD, yr 42.5±12.1 38.6±11.1 0.015
Age at onset of intestinal symptoms, yr 41.7±12.4 37.7±11.3 0.014
Age at diagnosis of BD, yr 39.8±12.5 35.9±11.0 0.018
Male sex 91 (46.9) 32 (42.1) 0.476
Disease duration, yr 7.4±5.1 7.8±4.6 0.511
Family history of BD 8 (4.1) 1 (1.3) 0.452
Symptoms and signs of BD
    Oral ulcer 175 (90.2) 74 (97.4) 0.073
    Genital ulcer 76 (39.2) 39 (51.3) 0.070
    Ocular lesion 35 (18.0) 16 (21.1) 0.570
    Skin lesions 81 (41.8) 36 (47.4) 0.402
    Arthritis/arthralgia 60 (30.9) 25 (32.9) 0.754
Laboratory findings at diagnosis
    WBC, 106/L 7,979±3,500 9,977±5,316 0.003
    Hemoglobin, g/dL 12.1±2.0 11.9±2.4 0.578
    ESR, mm/hr 32.5±25.9 42.7±31.3 0.013
    CRP, mg/dL 1.7±2.4 4.4±4.9 <0.001
    Albumin, g/dL 4.2±0.6 3.9±0.7 0.002
DAIBD* at diagnosis 61±40 95±47 <0.001
Shape of intestinal ulcer*
    Oval/geographic 129 (73.7) 35 (52.2) 0.001
    Volcano 46 (26.3) 32 (47.8)
Types of intestinal ulcer*
    Typical type 104 (59.4) 40 (59.7) 0.969
    Atypical type 71 (40.6) 27 (40.3)
Diagnostic subtypes of intestinal BD*
    Definite 79 (45.1) 34 (50.7) 0.137
    Probable 73 (41.7) 30 (44.8)
    Suspected 23 (13.1) 3 (4.5)
Intestinal complication
    Perforation 14 (7.2) 19 (25.0) <0.001
    Fistula† 7 (3.6) 13 (17.1) <0.001
    Stricture 12 (6.2) 6 (7.9) 0.613
    Abscess 5 (2.6) 3 (3.9) 0.691
Medication
    5-ASA/sulfasalazine 179 (92.3) 72 (94.7) 0.476
    Corticosteroids 70 (36.1) 65 (85.5) <0.001
    Azathiopurine/6-MP 38 (19.6) 48 (63.2) <0.001
Surgery‡ 40 (20.6) 45 (59.2) <0.001
Hospitalization§ 89 (45.9) 70 (92.1) <0.001
Data are presented as mean±SD or number (%).
CED, cumulative effective dose; BD, Behçet disease; WBC, white blood cell count; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; 
DAIBD, disease activity index for intestinal Behçet disease; 5-ASA, 5-aminosalicylic acid; 6-MP, 6-mercaptopurine.
*Twenty-eight patients who were first diagnosed with intestinal BD at the time of operation were excluded from the analysis of colonoscopic 
characteristics; †Excluded anal fistula formation; ‡Intestinal resection related to intestinal BD; §Intestinal BD-related admission.
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ing radiation exposure from diagnostic medical imaging in CD 
patients have reported that the mean CED for CD patients was 
14.3 to 36.1 mSv10-14,24 and the proportion of CD patients having 
an estimated CED ≥50 mSv was 7.0% to 23.7%.9,10,12-14 Our re-
sults showed that Korean intestinal BD patients were exposed to 
higher levels of ionizing radiation from diagnostic studies than 
Western CD patients, although they were indirectly compared. 
Because intestinal BD is rare, clinicians may have less experi-
ence with it and may thus order unnecessary radiologic exami-
nations. Our results suggest that Korean clinicians caring for in-
testinal BD patients need to be cautious of ordering unnecessary 
radiologic examinations. In addition, clinicians need to consider 
cumulative radiation exposure and perform radiologic examina-
tions only when the results can affect the patient’s management.
Our recent study found that there were no significant differ-
ences in the long-term clinical outcomes between CD and intes-
tinal BD and that CD patients required corticosteroid or immu-
nosuppressant therapy more often than intestinal BD patients.25 
Therefore, Korean intestinal BD patients may not be exposed to 
higher levels of diagnostic radiation than Korean CD patients. 
Actually, a very recent study of Korean CD patients reported 
that the mean CED was 53.6 mSv, and 34.7% of patients were 
exposed to high levels of radiation (CED >50 mSv).26
This study showed that approximately 80% of radiation ex-
posure in intestinal BD patients was from abdominal CT. Most 
studies on radiation exposure of IBD patients have also found 
that CT contributed the majority of the total effective dose ad-
ministered to IBD patients.10-13,24 Our recent study showed that 
intestinal complications such as intestinal fistulas, stricture, and 
abscesses were less frequent in intestinal BD than in CD and 
that small bowel involvement was uncommon in intestinal BD.25 
Moreover, most patients with intestinal BD have localized colon 
involvement with ileocecal concentration and thus colonoscopy 
may be sufficient to diagnose intestinal BD and identify disease 
extent. This suggests that the demand for CT examinations may 
be less in intestinal BD than in CD. However, contrary to our 
expectation, patients with intestinal BD were exposed to high 
levels of radiation owing to CT examination. The effective dose 
of radiation from CT is high compared to other modalities.22 
Therefore, reducing the number of unnecessary CT examina-
tions is critical to minimizing diagnostic medical radiation. It 
has been estimated that, in the United States, up to one-third 
of all CT scans are done when alternative modalities could be 
used with equal efficacy or are repeated unnecessarily.27 Recent 
advances in CT technology allow for significant reductions 
in radiation dose compared with current techniques.28 Several 
studies have shown that radiation dose can be reduced 30% to 
50% without sacrificing the diagnostic performance of CTE in 
CD patients.29-31 We suggest that low-dose CT profiles should 
be made available for intestinal BD patients at risk for high 
radiation exposure. Magnetic resonance (MR) enterography has 
recently emerged as a promising diagnostic tool in assessment 
of patients with CD. Several studies have reported that MR is 
not inferior to CT in diagnosing CD or assessing bowel damage 
in CD.32,33 MR enterography should be considered as an alterna-
tive diagnostic tool in assessment of patients with intestinal BD, 
although no data are available regarding the usefulness of MR 
enterography in intestinal BD. Further studies are warranted to 
confirm the availability of MR enterography in intestinal BD.
In this study, AZA/6-MP use, intestinal BD-related surgery, 
and hospitalization were independent predictors of increased 
radiation exposure for intestinal BD. Patients with clinical 
markers of increased disease severity such as requirement for 
immunosuppressants, surgery, or hospitalization underwent 
more diagnostic imaging modalities to guide further manage-
ment. AZA and 6-MP have been associated with an increased 
risk of lymphoma in IBD patients.7 Although lymphoma risk in 
intestinal BD patients treated with these medications has never 
been examined, AZA/6-MP use and radiation exposure by diag-
nostic imaging could synergistically increase the development 
of malignancies. Intestinal BD often requires surgical treatment 
because of the high frequency of acute complications such as 
intestinal perforations.19,34 Intestinal BD also recurs frequently, 
even after surgical treatment, and occasionally requires repeated 
surgery.19,34 The reason surgery was associated with increased 
radiation exposure could be because of repeated assessments 
Table 3. Multivariate Analysis for Factors Associated with Cumula-
tive Effective Dose ≥50 mSv
Factor OR 95% CI p-value
Age at diagnosis of intestinal BD, yr* 0.95 0.81-1.11 0.495
Age at onset of intestinal symptoms, yr* 1.00 0.88-1.14 0.987
Age at diagnosis of BD, yr* 1.04 0.95-1.14 0.404
Laboratory findings at diagnosis
    WBC, 106/L 1.00 1.00-1.00 0.141
    ESR, mm/hr 1.00 0.99-1.02 0.765
    CRP, mg/dL 1.10 0.96-1.27 0.158
    Albumin, g/dL 1.52 0.71-3.22 0.280
DAIBD* at diagnosis 0.99 0.98-1.01 0.499
Shape of intestinal ulcer
 (volcano vs oval/geographic)
0.70 0.30-1.63 0.405
Perforation 2.90 0.65-12.92 0.162
Fistula† 1.27 0.31-5.27 0.738
Corticosteroids 2.83 0.96-8.32 0.059
Azathiopurine/6-MP 2.60 1.10-6.16 0.030
Surgery‡ 3.35 1.20-9.39 0.022
Hospitalization§ 4.11 1.32-12.82 0.015
OR, odds ratio; CI, confidence interval; BD, Behçet disease; WBC, 
white blood cell count; ESR, erythrocyte sedimentation rate; CRP, C-
reactive protein; DAIBD, disease activity index for intestinal Behçet 
disease; 6-MP, 6-mercaptopurine.
*Mean±SD; †Excluded anal fistula formation; ‡Intestinal resection re-
lated to intestinal BD; §Intestinal BD-related admissions.
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actual exposure. However, we captured the DLP for approxi-
mately two-thirds of the CT scans performed and the calculated 
mean values (20.6 mSv) were similar to standard estimates of 
CT scans of the abdomen and pelvis (20 mSv). Finally, this was 
a hospital-based study and thus referral-center bias with inclu-
sion of more severe cases in our cohort cannot be excluded, 
although patients with intestinal BD are generally managed by 
gastroenterology specialists in Korea.
In conclusion, the exposure to diagnostic radiation in patients 
with intestinal BD was high, mainly due to CT examination. 
One in four patients with intestinal BD was exposed to harmful 
amounts of diagnostic radiation. Patients who required immu-
nosuppressants such as AZA/6-MP, surgery, or hospitalization 
were at greater risk of high radiation exposure. Given that intes-
tinal BD is a life-long illness, clinicians caring for patients with 
intestinal BD need to consider cumulative radiation exposure, 
particularly from repeated CT scanning, and should perform 
these examinations only when the results can affect the pa-
tient’s management. In addition, the availability of low-dose CT 
profiles and alternative imaging modalities such as MR imaging 
needs to be increased.
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